Corvus Pharmaceuticals, Inc. Depreciation
Corvus Pharmaceuticals, Inc. (CRVS) reported Depreciation of $623.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2017-11-02
- Corvus Pharmaceuticals, Inc. depreciation for the quarter ending 2017-09-30 was $211.00K, a 32.70% increase year-over-year.
- Corvus Pharmaceuticals, Inc. depreciation for the quarter ending 2017-06-30 was $208.00K, a 44.44% increase year-over-year.
- Corvus Pharmaceuticals, Inc. depreciation for the quarter ending 2017-03-31 was $204.00K, a 92.45% increase year-over-year.
- Corvus Pharmaceuticals, Inc. depreciation for the quarter ending 2016-12-31 was $185.00K, a 224.56% increase year-over-year.
- Corvus Pharmaceuticals, Inc. depreciation for fiscal 2016 was $594.00K, a 301.35% increase from fiscal 2015.
- Corvus Pharmaceuticals, Inc. depreciation for fiscal 2015 was $148.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2017-09-30 | $211.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $419.00K derived: sum of 2 quarters · filed 2017-11-02 | $623.00K 10-Q · filed 2017-11-02 | $808.00K derived: sum of 4 quarters · filed 2017-11-02 |
| 2017-06-30 | $208.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $412.00K 10-Q · filed 2017-08-03 | $597.00K derived: sum of 3 quarters · filed 2017-08-03 | $756.00K derived: sum of 4 quarters · filed 2017-11-02 |
| 2017-03-31 | $204.00K 10-Q · filed 2017-05-04 | $389.00K derived: sum of 2 quarters · filed 2017-05-04 | $548.00K derived: sum of 3 quarters · filed 2017-11-02 | $692.00K derived: sum of 4 quarters · filed 2017-11-02 |
| 2016-12-31 | $185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $344.00K derived: sum of 2 quarters · filed 2017-11-02 | $488.00K derived: sum of 3 quarters · filed 2017-11-02 | $594.00K 10-K · filed 2017-03-10 |
| 2016-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $303.00K derived: sum of 2 quarters · filed 2017-11-02 | $409.00K 10-Q · filed 2017-11-02 | $466.00K derived: sum of 4 quarters · filed 2017-11-02 |
| 2016-06-30 | $144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $250.00K 10-Q · filed 2017-08-03 | $307.00K derived: sum of 3 quarters · filed 2017-08-03 | $362.00K derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-03-31 | $106.00K 10-Q · filed 2017-05-04 | $163.00K derived: sum of 2 quarters · filed 2017-05-04 | $218.00K derived: sum of 3 quarters · filed 2017-05-04 | $253.00K derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $112.00K derived: sum of 2 quarters · filed 2017-03-10 | $147.00K derived: sum of 3 quarters · filed 2017-03-10 | $148.00K 10-K · filed 2017-03-10 |
| 2015-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $90.00K derived: sum of 2 quarters · filed 2016-11-03 | $91.00K 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $36.00K 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $1.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |